Sunev Pharma Solutions Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 13-12-2024
- Paid Up Capital ₹ 4.62 M
as on 13-12-2024
- Company Age 17 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 19.50 Cr
as on 13-12-2024
- Revenue 50.18%
(FY 2022)
- Profit 34.48%
(FY 2022)
- Ebitda 46.02%
(FY 2022)
- Net Worth -0.37%
(FY 2022)
- Total Assets 0.04%
(FY 2022)
About Sunev Pharma Solutions
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.62 M.
The company has closed loans amounting to ₹19.50 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Pawan Chaudhary, Manu Chaudhary, and Ashutosh Jain serve as directors at the Company.
- CIN/LLPIN
U24232CH2006PLC030653
- Company No.
030653
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
26 Dec 2006
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sunev Pharma Solutions?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manu Chaudhary  | Director | 26-Dec-2006 | Current |
| Pawan Chaudhary | Director | 26-Dec-2006 | Current |
| Ashutosh Jain | Director | 02-Jan-2007 | Current |
Financial Performance and Corporate Structure Insights of Sunev Pharma Solutions.
Sunev Pharma Solutions Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 50.18% increase. The company also saw a substantial improvement in profitability, with a 34.48% increase in profit. The company's net worth dipped by a decrease of 0.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sunev Pharma Solutions?
In 2022, Sunev Pharma Solutions had a promoter holding of 99.99% and a public holding of 0.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Venus Remedies LimitedActive 35 years 3 monthsPawan Chaudhary, Manu Chaudhary and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Dena Bank Creation Date: 26 Nov 2013 | ₹14.50 Cr | Satisfied |
Allahabad Bank Creation Date: 12 Oct 2010 | ₹3.50 Cr | Satisfied |
Allahabad Bank Creation Date: 12 Oct 2010 | ₹1.50 Cr | Satisfied |
How Many Employees Work at Sunev Pharma Solutions?
Unlock and access historical data on people associated with Sunev Pharma Solutions, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sunev Pharma Solutions, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sunev Pharma Solutions's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
